Table 2.
Log-rank test for characteristics of survival in 75 patients
| Variables | n | OS (mo) | log-rank test P values |
|---|---|---|---|
| Gender | |||
| Female | 9 | 12.2 ± 1.79 | 0.753 |
| Male | 66 | 13.4 ± 1.15 | |
| Age | |||
| < 50 | 27 | 12.5 ± 1.43 | 0.613 |
| ≥ 50 | 48 | 13.6 ± 1.38 | |
| Child-Pugh classification | |||
| A | 66 | 13.9 ± 1.09 | < 0.001 |
| B | 9 | 6.4 ± 0.80 | |
| Performance status | |||
| 0 | 17 | 14.3 ± 2.39 | 0.728 |
| 1 | 58 | 12.9 ± 1.11 | |
| HBsAg | |||
| Negative | 6 | 15.5 ± 2.41 | 0.462 |
| Positive | 69 | 12.9 ± 1.09 | |
| AFP (μg/L) | |||
| < 400 | 44 | 14.8 ± 1.59 | 0.041 |
| ≥ 400 | 31 | 10.9 ± 0.92 | |
| No. of prior therapies | |||
| < 4 | 35 | 12.8 ± 1.43 | 0.648 |
| ≥ 4 | 40 | 13.6 ± 1.44 | |
| Intrahepatic tumor number | |||
| Solitary | 54 | 15.1 ± 1.25 | < 0.001 |
| Multiple | 21 | 7.6 ± 0.59 | |
| LN metastases | |||
| Absent | 66 | 13.6 ± 1.11 | 0.223 |
| Present | 9 | 10.6 ± 2.51 | |
| Distant metastases | |||
| Absent | 55 | 14.7 ± 1.29 | 0.001 |
| Present | 20 | 8.8 ± 0.58 | |
| PTV | |||
| TT | 29 | 7.6 ± 0.61 | < 0.001 |
| TT + PT | 46 | 16.3 ± 1.34 | |
| BED Dose (Gy) | |||
| < 55 | 43 | 10.5 ± 0.97 | 0.001 |
| ≥ 55 | 32 | 16.6 ± 1.76 | |
| Further radiotherapy | |||
| Yes | 37 | 17.3 ± 1.58 | < 0.001 |
| No | 38 | 8.6 ± 0.59 | |
| Thrombus location | |||
| IVC only | 57 | 13.8 ± 1.13 | 0.205 |
| IVC + RA | 18 | 11.6 ± 2.48 | |
Abbreviations: OS overall survival, AFP α-fetoprotein, LN lymphonodus, TT tumor thrombus, PTV planning target volume, PT primary tumors, BED biological effective dose, IVC inferior vena cava, RA right atrium